



CURRICULUM VITAE

Timothy F. O’Neill, MD

Joined Los Alamitos Cardiovascular as a partner in 1997

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | www.losalcardio.com

Specialties:	Internal Medicine, Cardiology
Board Certifications:	<ul style="list-style-type: none"> • Certified in Cardiovascular Disease American Board of Internal Medicine 1993 (Recertification 2009) • Certified in Internal Medicine American Board of Internal Medicine 1990 • National Board Parts I,II,III National Board of Medical Examiners 1985 – 1988
Research Experience:	<ul style="list-style-type: none"> • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome. Sub-Investigator 2019 Sponsor: CSL Behring LLC NCT03473223: https://clinicaltrials.gov/ct2/show/NCT03473223 • COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots). Sub-Investigator 2018 – Present Sponsor : Patient-Centered Outcomes Research Institute (PCORI) NCT03196349: https://clinicaltrials.gov/ct2/show/NCT03196349

- **NODE 301:** Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
 Sub-Investigator | 2019
 Sponsor: Milestone Pharmaceuticals Inc.
 NCT03464019: <https://clinicaltrials.gov/ct2/show/NCT03464019>
- **NODE 302:** Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
 Sub-Investigator | 2019
 Sponsor: Milestone Pharmaceuticals Inc.
 NCT03635996: <https://clinicaltrials.gov/ct2/show/NCT03635996>
- **PARADISE MI:** A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
 Sub-Investigator | 2018 – Present
 Sponsor: Novartis
 NCT02924727: <https://clinicaltrials.gov/ct2/show/NCT02924727>
- **PEA-VALVE:** Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
 Sub-Investigator | 2018 – Present
 Sponsor: Eko Devices
- **GALACTIC-HF:** Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
 Sub-Investigator | 2017 – Present
 Sponsor: Amgen
 NCT02929329: <https://clinicaltrials.gov/ct2/show/NCT02929329>
- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
 Sub-Investigator | 2017 – 2019
 Sponsor: Novartis
 NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>

- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
 Sub-Investigator | 2016 – Present
 Sponsor: CVRx, Inc.
 NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
 Sub-Investigator | 2016 – 2017
 Sponsor: Gilead/ICON
- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
 Sub-Investigator | 2015 – Present
 Sponsor: AstraZeneca
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
 Sub-Investigator | 2015 – 2016
 Sponsor: Amgen, Evidera
- **DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
 Sub-Investigator | 2013 – 2018
 Sponsor: AstraZeneca
 NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>
- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
 Sub-Investigator | 2013 – 2017
 Sponsor: Sanofi
 NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>

- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**
 Sub-Investigator | 2013 – 2017
 Sponsor: Yale University School of Medicine/NIH
 NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
 Sub-Investigator | 2013 – 2014
 Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**
 Sub-Investigator | 2013
 Sponsor: Tasly Pharmaceuticals
 NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
 Sub-Investigator | 2013 – 2018
 Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
 NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>
- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.**
 Sub-Investigator | 2012
 Sponsor: Alere San Diego
- **Mission® PT Coagulation Monitoring System Clinical Study.**
 Sub-Investigator | 2012
 Sponsor: ACON Laboratories, INC.
- **The “BRIDGE” Trial (1U01HL08675501A1):** Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
 Sub-Investigator | 2012 – 2015
 Sponsor: National Institutes of Health (NIH) – National Heart, Lung and Blood Institute (NHLBI)

NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>

- **GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
Sub-Investigator | 2012 – Present
Sponsor: Boehringer Ingelheim
NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- **BRADY-CARE:** Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
Sub-Investigator | 2010 – 2012
Sponsor: St. Jude Medical Center
NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>
- **The PROMISE Trial:** PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
Sub-Investigator | 2010 – 2014
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>
- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Sub-Investigator | 2010 – 2017
Sponsor: Janssen Scientific Affairs, LLC
Collaborator: Duke Clinical Research
NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>
NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>
- **RATE:** Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00837798 | <http://clinicaltrials.gov/ct2/show/NCT00837798>
- **FREEDOM:** A Frequent Optimization Study the Quick Opt™ Method.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00418314 | <http://clinicaltrials.gov/ct2/show/NCT00418314>
- **ENGAGE:** Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Sub-Investigator | 2009 – 2015

	<p>Sponsor: Daiichi Sankyo Pharma Development NCT00781391 http://clinicaltrials.gov/ct2/show/record/NCT00781391</p>
<p>Current Hospital Appointments:</p>	<ul style="list-style-type: none"> • Los Alamitos Medical Center 3751 Katella Avenue Los Alamitos, California 90720 • MemorialCare Health System Long Beach Memorial Medical Center 2801 Atlantic Avenue Long Beach, California 90801 • Lakewood Regional Medical Center 3700 South Street Lakewood, California 90712
<p>Work History:</p>	<ul style="list-style-type: none"> • Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc. Cardiologist Los Alamitos, California February 1997 – Present • Heart Institute of the Desert Rancho Mirage, California October 1993 – February 1997
<p>Education:</p>	<ul style="list-style-type: none"> • Pacemaker Fellowship Long Beach Memorial Medical Center Long Beach, California July 1992 – June 1993 • Cardiology Fellowship University of California, Irvine Medical Center Irvine, California July 1990 – June 1993 • Internal Medicine Residency University of California, Irvine Medical Center Irvine, California June 1987 – June 1990 • University of New Mexico School of Medicine Doctor of Medicine Degree Albuquerque, New Mexico August 1983 – May 1987

	<ul style="list-style-type: none"> • Undergraduate Education Creighton University Omaha, Nebraska Bachelor of Arts Degree in History, <i>Summa Cum Laude</i> August 1979 – May 1983
Educational Honors and Awards:	<ul style="list-style-type: none"> • Outstanding Intern Commendation Veteran’s Administration Medical Center Long Beach, California 1987 • Four Superior Scholastic Achievement Awards Creighton University 1980 – 1983 • Graduated Summa Cum Laude Creighton University 1983
Clinical Expertise:	<p>Non-Invasive Cardiology Echocardiography, TEE, Dobutamine and Stress Echo</p> <p>Invasive Cardiology Catheterization, Permanent Pacemaker Implantation</p>
Medical License:	California , 1989